Nuvaring
Product Images NDC 50090-1008

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Nuvaring (NDC 50090-1008). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500901008)

NUVARING vaginal ring packaging label from A-S Medication Solutions showing the product NDC 50090-1008-0 with active ingredient dosage of 0.120MG and 0.015MG. The label includes storage instructions to store at 36 to 46 degrees Fahrenheit and to avoid direct sunlight. It also notes that the package contains 1 ring.*

FDA Label Image

Figure 1 (Nuvaring 01)

A horizontal bar chart showing the number of women with a blood clot out of 10,000 woman-years for different groups: Non-CHC User Non-Pregnant (1 to 5), CHC-User (3 to 12), Pregnancy (5 to 20), and Postpartum (12 weeks only) with the highest range from 40 to 65.*

FDA Label Image

Chemical Structure (Nuvaring 02)

Chemical structure diagrams of the active ingredients etonogestrel (C22H28O2) and ethinyl estradiol (C20H24O2) as shown. These are steroidal compounds with specific arrangements of hydroxyl, methyl, and alkyne groups.*

FDA Label Image

Figure 2 (Nuvaring 03)

A line graph illustrating the plasma concentration of etonogestrel and ethinyloestradiol (EE) over 21 days following NuvaRing insertion. The y-axes show etonogestrel levels in pg/mL and EE levels in pg/mL, while the x-axis displays days after insertion. Etonogestrel levels rise sharply then plateau, and EE levels remain relatively constant throughout.*

FDA Label Image

Figure 3 (Nuvaring 04)

An illustration showing contraceptive methods categorized by their effectiveness based on pregnancy rates per 100 women per year. It lists implants, injections, intrauterine devices, and sterilization as having fewer than 1 pregnancy; birth control pills, skin patches, and vaginal rings with hormones as next most effective; condoms and diaphragms as moderately effective; abstinence during fertile days, spermicide, and withdrawal as less effective; and no birth control as resulting in the most pregnancies.*

FDA Label Image

Figure 4 (Nuvaring 05)

A horizontal bar chart depicting the number of women with a blood clot per 10,000 woman-years across four categories: Non-CHC users who are non-pregnant, CHC users, pregnant women, and postpartum women within 12 weeks. Each category shows ranges of blood clot incidence, with postpartum women having the highest range from 40 to 65.*

FDA Label Image

Figure A, Figure B, Figure C (Nuvaring 06)

Illustrations showing three different body postures for using or inserting a vaginal ring (NuvaRing). Figure A depicts a person lying on their back with knees bent; Figure B shows a person squatting; Figure C illustrates a person standing with one leg elevated on a surface.*

FDA Label Image

Figure D, Figure E (Nuvaring 07)

Illustrations showing hands holding a NuvaRing contraceptive vaginal ring. Figure D depicts holding the ring by pinching it between the thumb and index finger around the outer edge. Figure E shows the ring compressed between the thumb and index finger, preparing it for insertion.*

FDA Label Image

Figure F (Nuvaring 08)

An instructional anatomical diagram showing the placement of the NuvaRing vaginal contraceptive. The illustration labels the uterus, vagina, and the NuvaRing positioned inside the vagina.*

FDA Label Image

Figure G (Nuvaring 09)

An instructional anatomical diagram demonstrating the proper insertion of the NUVARING vaginal contraceptive ring into the vagina. The grayscale illustration shows a hand inserting the ring toward the cervix inside a cross-section of female pelvic anatomy.*

FDA Label Image

Figure H (Nuvaring 10)

An anatomical illustration showing a sagittal cross-section of female pelvic organs with a depiction of the NuvaRing vaginal ring contraceptive inserted inside the vagina near the cervix, demonstrating its placement for use.*

FDA Label Image

Figure I (Nuvaring 11)

An anatomical illustration showing a sagittal cross-section of the female pelvis, depicting the placement of NUVARING vaginal ring inside the vaginal canal near the cervix.*

FDA Label Image

Figure J (Nuvaring 12)

An anatomical illustration demonstrating the correct insertion of a vaginal ring. The image shows a hand placing the ring inside the vaginal canal to position the product properly for use.*

FDA Label Image

Figure 1a (Nuvaring 13)

An instructional illustration labeled '1a' showing a hand being washed under running water from a faucet, depicting the initial step of hand hygiene or preparation.*

FDA Label Image

Figure 1b (Nuvaring 14)

An instructional diagram showing the components of a NUVARING vaginal contraceptive ring applicator, labeled parts include the plunger (A), the main barrel (B), the protective sheath (C), the rounded tip (D), and the NUVARING vaginal ring itself (E). This image illustrates how the applicator and ring are assembled and positioned for use.*

FDA Label Image

Figure 2a (Nuvaring 15)

An instructional illustration showing two hands holding a flexible ring-shaped device, with an arrow indicating the direction to squeeze or compress the ring. This image is part of the usage instructions for NUVARING, a vaginal contraceptive ring by A-S Medication Solutions.*

FDA Label Image

Figure 2b (Nuvaring 16)

An instructional illustration showing two hands handling a flexible ring-shaped device, with one hand holding the device and the other pulling or unwrapping a loop or tab from it. The image is labeled "2b" in a solid circle at the upper left corner.*

FDA Label Image

Figure 2c (Nuvaring 17)

An instructional illustration showing two hands preparing to insert the NUVARING vaginal ring. One hand holds the NUVARING applicator aimed toward a simplified vaginal outline, while the other hand is pulling the ring inside the applicator, demonstrating the insertion step for proper placement.*

FDA Label Image

Figure 2d (Nuvaring 18)

An instructional illustration in three panels depicting a woman removing NUVARING. The first panel shows the woman lying on her back with knees bent and hands reaching downward. The second panel shows her squatting and reaching to grasp the ring. The third panel illustrates her standing with one leg raised, holding the ring for removal.*

FDA Label Image

Figure 3a (Nuvaring 19)

An instructional diagram showing a hand holding a small flexible ring and a syringe-like applicator. The illustration appears to depict preparation or insertion steps related to the NUVARING contraceptive vaginal ring.*

FDA Label Image

Figure 3b (Nuvaring 20)

An instructional illustration labeled '3b' showing a hand inserting a flexible ring-shaped device into the vaginal canal, demonstrating the proper placement technique for NUVARING.*

FDA Label Image

Figure 3c (Nuvaring 21)

An instructional diagram showing the insertion of a NuvaRing vaginal ring into the vaginal canal using the fingers. The illustration highlights the placement technique for this hormonal contraceptive device labeled by A-S Medication Solutions.*

FDA Label Image

Figure 3d (Nuvaring 22)

Illustration showing a hand holding a NuvaRing device above a wastebasket, representing proper disposal of the contraceptive vaginal ring. The image emphasizes discarding the used ring by placing it into a trash receptacle.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.